Longport, Inc.
LPTI
Other OTC0.00
USD
- -
- -
Longport, Inc.
LPTI
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Longport, Inc. (LPTI) develops, manufactures, markets and sells high-resolution ultrasound imaging systems for medical applications, primarily in the United States with exports to other markets; its core product is the EPISCAN I-200, a point-of-care imaging system equipped with interchangeable probes operating at frequencies between 20 and 50MHz to visualize skin and underlying soft tissue, serving sectors including wound assessment and prevention, clinical dermatology, aesthetics and plastics, burn assessment, superficial musculoskeletal imaging, research validation of skin-impacting products and veterinary uses. The EPISCAN I-200 holds FDA and CE marketing clearance and distinguishes itself through superior resolution compared to conventional ultrasound systems. Founded in 1993 as a Delaware corporation and headquartered in Chadds Ford, Pennsylvania, Longport shifted its strategic focus to high-resolution medical ultrasound in 1999, targeting the multibillion-dollar U.S. market for skin diseases and aesthetic procedures while dedicating resources to technology extension, new applications and emerging markets. No major acquisitions, funding rounds, partnerships, product launches or strategic reorganizations have been publicly reported in the last 1-2 years, with the company maintaining steady operations amid trailing twelve-month revenue of approximately $1.19 million.